ViroGates (VIRO) Q4 2025 earnings summary

Executive summary

• Achieved proof of concept for suPARnostic POC+ targeting the longevity testing market.

• Received FDA feedback confirming De Novo pathway for suPARnostic TurbiLatex, providing regulatory clarity.

• Deepened commercial partnership with suPARbio in the U.S., with increased commitment from their investment entity.

• Raised DKK 19.3 million in a directed capital raise, strengthening the cash position.

• Significant steps taken towards EU IVDR compliance.

Financial highlights

• Revenue grew 8% year-over-year to DKK 5.3 million, driven by traction in preventive health and longevity.

• Net loss improved by 28% to DKK 10.4 million from DKK 14.3 million in 2024.

• Other income increased 60% to DKK 3.6 million, reflecting ongoing Sobi collaboration.

• Operating expenses reduced by 17%, mainly due to lower sales and distribution costs after a late 2024 reorganization.

• Operating cash burn dropped from DKK 12 million in 2024 to DKK 4.1 million in 2025.

Outlook and guidance

• POC+ product expected to be available late 2026 or early 2027, pending clinical verification and IVDR process.

• De Novo FDA filing for suPARnostic TurbiLatex planned for the first half of 2026.

• Focus on expanding partnerships and distributor models, especially in new markets like Poland.

• Continued emphasis on preventive health and longevity market segments.